--- title: "U.S. stock night market fluctuations: Fate Therapeutics rose 7.22% in after-hours trading, analysts raised the target price and the CAR T therapy presentation boosted market confidence" type: "News" locale: "en" url: "https://longbridge.com/en/news/285141782.md" description: "Fate Therap rose 7.22% in the night session; BeiGene fell 1.99% in the night session, with a transaction volume of USD 92,300; Compass Therapeutics rose 1.03% in the night session, with a transaction volume of USD 43,800; Cellularity rose 1.14% in the night session, with a transaction volume of USD 39,200" datetime: "2026-05-05T01:41:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285141782.md) - [en](https://longbridge.com/en/news/285141782.md) - [zh-HK](https://longbridge.com/zh-HK/news/285141782.md) --- # U.S. stock night market fluctuations: Fate Therapeutics rose 7.22% in after-hours trading, analysts raised the target price and the CAR T therapy presentation boosted market confidence **U.S. Stock Night Market Movements** Fate Therapeutics rose 7.22% in the night market. Based on recent key news: 1. On May 4, HC Wainwright & Co. maintained a buy rating on Fate Therapeutics and raised the target price from $5 to $7. This positive analyst rating drove the stock price up. 2. On May 4, Fate Therapeutics announced three presentations on ready-to-use CAR T cell therapies covering cancer and autoimmune diseases at the 2026 ASGCT annual meeting. These presentations enhanced market confidence in the company's R&D pipeline, further driving the stock price up. 3. On May 1, Fate Therapeutics granted a newly hired non-executive employee 30,200 restricted stock units (RSUs) as part of an inducement equity plan. This news reflects the company's proactive measures in attracting talent, boosting investor confidence. The biotechnology sector has performed strongly recently, with significant capital inflows. **Stocks with High Trading Volume in the Industry** BeiGene fell 1.99% in the night market. Based on recent key news: 1. On May 4, Wells Fargo announced a target price of $400 per share for BeOne Medicines. This news may have negatively impacted BeiGene's stock price, as investors might perceive BeOne Medicines' prospects as more optimistic, thereby reallocating some investment funds. 2. On May 4, Refinitiv released BeiGene's quarterly earnings report. The report showed that BeiGene's actual earnings per share for Q1 2025 were $0.01, far exceeding the expected -$0.72, resulting in a 101.4% surprise. However, despite the earnings beating expectations, the market reaction remained negative, leading to a decline in stock price. 3. On May 4, BeiGene's earnings per share for Q4 2024 were -$1.43, below the expected -$0.89, missing by 60.9%. This news may have intensified investor concerns about the company's future profitability, further driving the stock price down. The overall market performance is weak, with cautious capital flows. Compass Therapeutics rose 1.03% in the night market, with a trading volume of $43,800, and no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. Cellectis rose 1.14% in the night market. Based on recent key news: 1. On May 4, Cellectis announced that it would release the top-line results of the ACACIA-HCM pivotal Phase 3 clinical trial on May 5. This news triggered positive market expectations for the company's future development, driving the stock price up On May 4th, the company's Executive Vice President and Chief Business Officer Andrew Callos sold 15,857 shares of Cell Dynamics stock for a transaction amount of $1,030,705. This move may raise concerns in the market about insider confidence in the company, putting some pressure on the stock price in the short term. The biotechnology industry has recently gained increased attention ### Related Stocks - [FATE.US](https://longbridge.com/en/quote/FATE.US.md) - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md) - [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md) ## Related News & Research - [Fate Therapeutics Q4 Earnings Summary & Key Takeaways](https://longbridge.com/en/news/277057214.md) - [Nvidia's "big test" on Wednesday: The battle that will determine the fate of the AI bull market is here.](https://longbridge.com/en/news/286909870.md) - [Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences](https://longbridge.com/en/news/282206169.md) - [Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference](https://longbridge.com/en/news/282940584.md) - [Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation](https://longbridge.com/en/news/286495998.md)